Narrow search
Showing 1 - 10 of 127
Cover Image
Pharmaceutical Innovation and Cancer Survival
Lichtenberg, Frank R.; Jonsson, Bengt; Wilking, Nils - 2014
, expected survival, number of people diagnosed, and innovation in diagnostic, radiation, and surgical procedures. We find that …
Persistent link: https://www.econbiz.de/10014049989
Cover Image
Are patients more adherent to newer drugs?
Blankart, Katharina; Lichtenberg, Frank R. - In: Health care management science : a new journal serving … 23 (2020) 4, pp. 605-618
Persistent link: https://www.econbiz.de/10012426492
Cover Image
Chapter 15 Economics of defense R&D
Lichtenberg, Frank R. - In: Handbook of defense economics : volume 1, (pp. 431-457). 1995
This chapter examines a number of aspects of defense R&D, including: mechanisms — design competitions, and independent R&D subsidies — used by the US government to encourage firms to invest their own funds in defense R&D; theory and evidence concerning both the private and social benefits of,...
Persistent link: https://www.econbiz.de/10014024416
Cover Image
The benefits and costs of newer drugs : evidence from the 1996 medical expenditure panel survey
Lichtenberg, Frank R. - 2000
The nation's spending for prescription drugs has grown dramatically in recent years. Previous studies have shown that the replacement of older drugs by newer, more expensive, drugs is the single most important reason for this increase, but they did not measure how much of the difference between...
Persistent link: https://www.econbiz.de/10011397709
Cover Image
Sources of US longevity increase, 1960 - 1997
Lichtenberg, Frank R. - 2000
annual U.S. time-series data on life expectancy, health expenditure, and medical innovation. Reliable annual data are … available for only one type of innovation G new drugs G but pharmaceutical R&D accounts for a significant fraction of total … biomedical research. The empirical analysis provides strong support for the hypothesis that both medical innovation (in the form …
Persistent link: https://www.econbiz.de/10011397757
Cover Image
The Benefits and Costs of Newer Drugs : Evidence from the 1996 Medical Expenditure Panel Survey
Lichtenberg, Frank R. - 2004
The nation's spending for prescription drugs has grown dramatically in recent years. Previous studies have shown that the replacement of older drugs by newer, more expensive, drugs is the single most important reason for this increase, but they did not measure how much of the difference between...
Persistent link: https://www.econbiz.de/10012786243
Cover Image
Sources of U.S. Longevity Increase, 1960 - 1997
Lichtenberg, Frank R. - 2021
U.S. time-series data on life expectancy, health expenditure, and medical innovation. Reliable annual data are available … for only one type of innovation new drugs but pharmaceutical R&D accounts for a significant fraction of total biomedical … research. The empirical analysis provides strong support for the hypothesis that both medical innovation (in the form of new …
Persistent link: https://www.econbiz.de/10013321143
Cover Image
The impact of new drug launches on longevity growth in nine Middle Eastern and African countries, 2007-2015
Lichtenberg, Frank R. - In: Review of Middle East economics and finance 14 (2018) 3, pp. 1-15
Persistent link: https://www.econbiz.de/10011964261
Cover Image
The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997 - 2010 : evidence from longitudinal, disease-level data
Lichtenberg, Frank R.; Pettersson, Billie - In: Economics of innovation and new technology 23 (2014) 3/4, pp. 239-273
Persistent link: https://www.econbiz.de/10010407486
Cover Image
Has medical innovation reduced cancer mortality?
Lichtenberg, Frank R. - In: CESifo economic studies : CESifo, a joint initiative of … 60 (2014) 1, pp. 135-177
I analyze the effects of four types of medical innovation and cancer incidence on US cancer mortality rates during the … pre‐dated factors that drove both innovation and mortality and that there would have been parallel trends in mortality in … the absence of innovation, the estimates indicate that there were three major sources of the 13.8% decline of the age …
Persistent link: https://www.econbiz.de/10010466909